Cancers, Vol. 13, Pages 4395: Kallikrein 5 Inhibition by the Lympho-Epithelial Kazal-Type Related Inhibitor Hinders Matriptase-Dependent Carcinogenesis
Cancers, Vol. 13, Pages 4395: Kallikrein 5 Inhibition by the Lympho-Epithelial Kazal-Type Related Inhibitor Hinders Matriptase-Dependent Carcinogenesis
Cancers doi: 10.3390/cancers13174395
Authors:
Elaine Zayas Marcelino da Silva
Thais Fernanda de Campos Fraga-Silva
Yao Yuan
Márcia Gaião Alves
Gabriel Azevedo Publio
Carol Kobori da Fonseca
Márcio Hideki Kodama
Gabriel Viliod Vieira
Marina Ferreira Candido
Lara Maria Alencar Ramos Innocentini
Mateus Gonçalves Miranda
Alfredo Ribeiro da Silva
Jose Carlos Alves-Filho
Vania Luiza Deperon Bonato
Ramiro Iglesias-Bartolome
Katiuchia Uzzun Sales
Head and neck squamous cell carcinoma remains challenging to treat with no improvement in survival rates over the past 50 years. Thus, there is an urgent need to discover more reliable therapeutic targets and biomarkers for HNSCC. Matriptase, a type-II transmembrane serine protease, induces malignant transformation in epithelial stem cells through proteolytic activation of pro-HGF and PAR-2, triggering PI3K-AKT-mTOR and NFKB signaling. The serine protease inhibitor lympho-epithelial Kazal-type-related inhibitor (LEKTI) inhibits the matriptase-driven proteolytic pathway, directly blocking kallikreins in epithelial differentiation. Hence, we hypothesized LEKTI could inhibit matriptase-dependent squamous cell carcinogenesis, thus implicating kallikreins in this process. Double-transgenic mice with simultaneous expression of matriptase and LEKTI under the...
Source: Cancers - Category: Cancer & Oncology Authors: Elaine Zayas Marcelino da Silva Thais Fernanda de Campos Fraga-Silva Yao Yuan M árcia Gaião Alves Gabriel Azevedo Publio Carol Kobori da Fonseca M árcio Hideki Kodama Gabriel Viliod Vieira Marina Ferreira Candido Lara Maria Alencar Ramos Innocentini Ma Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Epithelial Cancer | Head and Neck Cancer | HNSCC | Oral Cancer | Skin | Skin Cancer | Squamous Cell Carcinoma | Stem Cell Therapy | Stem Cells